Cystic Fibrosis - Pipeline Review, H2 2018

Global Markets Direct’s, ‘Cystic Fibrosis - Pipeline Review, H2 2018’, provides an overview of the Cystic Fibrosis pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Cystic Fibrosis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Cystic Fibrosis and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Cystic Fibrosis

- The report reviews pipeline therapeutics for Cystic Fibrosis by companies and universities/research institutes based on information derived from company and industry-specific sources

- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

- The report reviews key players involved Cystic Fibrosis therapeutics and enlists all their major and minor projects

- The report assesses Cystic Fibrosis therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

- The report summarizes all the dormant and discontinued pipeline projects

- The report reviews latest news related to pipeline therapeutics for Cystic Fibrosis

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of therapeutics under development for Cystic Fibrosis

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Cystic Fibrosis pipeline depth and focus of Indication therapeutics

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

4D Molecular Therapeutics Inc

Advanced Inhalation Therapies (AIT) Ltd

Aeolus Pharmaceuticals Inc

AGILeBiotics BV

Alaxia SAS

AlgiPharma AS

AmpliPhi Biosciences Corp

Antabio SAS

Arch Biopartners ...

4D Molecular Therapeutics Inc

Advanced Inhalation Therapies (AIT) Ltd

Aeolus Pharmaceuticals Inc

AGILeBiotics BV

Alaxia SAS

AlgiPharma AS

AmpliPhi Biosciences Corp

Antabio SAS

Arch Biopartners Inc

Arcturus Therapeutics Ltd

Aridis Pharmaceuticals Inc

Arrowhead Pharmaceuticals Inc

AstraZeneca Plc

Boehringer Ingelheim GmbH

Calithera Biosciences Inc

Catabasis Pharmaceuticals Inc

Celtaxsys Inc

Chiesi Farmaceutici SpA

Cilian AG

CRISPR Therapeutics

Cyclacel Pharmaceuticals Inc

Cyclenium Pharma Inc

DiscoveryBiomed Inc

Editas Medicine Inc

Eloxx Pharmaceuticals Inc

Enterprise Therapeutics Ltd

Errant Gene Therapeutics LLC

ethris GmbH

Evaxion Biotech ApS

Galapagos NV

Generation Bio Corp

Grifols SA

Grupo Praxis Pharmaceutical SA

Helperby Therapeutics Group Ltd

Homology Medicines, Inc.

Horizon Pharma Plc

ID Pharma Co Ltd

Idorsia Pharmaceutical Ltd

Immun System IMS AB

Insmed Inc

Invion Ltd

Ionis Pharmaceuticals Inc

JHL Biotech Inc

Johnson & Johnson

Kamada Ltd

Kyorin Pharmaceutical Co Ltd

Lamellar Biomedical Ltd

Laurent Pharmaceuticals Inc

Lexicon Pharmaceuticals Inc

Microbion Corp

Novabiotics Ltd

Novartis AG

Onspira Therapeutics Inc

Paranta Biosciences Ltd

Parion Sciences Inc

Pharmaxis Ltd

PhaseBio Pharmaceuticals Inc

Polyphor AG

Progenra Inc

ProQR Therapeutics NV

Protalix BioTherapeutics Inc

Proteostasis Therapeutics Inc

Pulmatrix Inc

ReveraGen BioPharma Inc

Santhera Pharmaceuticals Holding AG

Sequoia Sciences Inc

Shire Plc

SolAeroMed Inc

Synedgen Inc

Synovo GmbH

Translate Bio Inc

Vanda Pharmaceuticals Inc

Verona Pharma Plc

Vertex Pharmaceuticals Inc

Vironika LLC

Table of Contents

Table of Contents

Table of Contents 2

Introduction 6

Cystic Fibrosis – Overview 7

Cystic Fibrosis – Therapeutics Development 8

Cystic Fibrosis – Therapeutics Assessment ...

Table of Contents

Table of Contents 2

Introduction 6

Cystic Fibrosis – Overview 7

Cystic Fibrosis – Therapeutics Development 8

Cystic Fibrosis – Therapeutics Assessment 29

Cystic Fibrosis – Companies Involved in Therapeutics Development 41

Cystic Fibrosis – Drug Profiles 76

Cystic Fibrosis – Dormant Projects 395

Cystic Fibrosis – Discontinued Products 403

Cystic Fibrosis – Product Development Milestones 404

Appendix 417

List of Tables

List of Tables

Number of Products under Development for Cystic Fibrosis, H2 2018

Number of Products under Development by Companies, H2 2018

Number of Products ...

List of Tables

Number of Products under Development for Cystic Fibrosis, H2 2018

Number of Products under Development by Companies, H2 2018

Number of Products under Development by Universities/Institutes, H2 2018

Products under Development by Companies, H2 2018

Products under Development by Universities/Institutes, H2 2018

Number of Products by Stage and Target, H2 2018

Number of Products by Stage and Mechanism of Action, H2 2018

Number of Products by Stage and Route of Administration, H2 2018

Number of Products by Stage and Molecule Type, H2 2018

Cystic Fibrosis – Pipeline by 4D Molecular Therapeutics Inc, H2 2018

Cystic Fibrosis – Pipeline by Advanced Inhalation Therapies (AIT) Ltd, H2 2018

Cystic Fibrosis – Pipeline by Aeolus Pharmaceuticals Inc, H2 2018

Cystic Fibrosis – Pipeline by AGILeBiotics BV, H2 2018

Cystic Fibrosis – Pipeline by Alaxia SAS, H2 2018

Cystic Fibrosis – Pipeline by AlgiPharma AS, H2 2018

Cystic Fibrosis – Pipeline by AmpliPhi Biosciences Corp, H2 2018

Cystic Fibrosis – Pipeline by Antabio SAS, H2 2018

Cystic Fibrosis – Pipeline by Arch Biopartners Inc, H2 2018

Cystic Fibrosis – Pipeline by Arcturus Therapeutics Ltd, H2 2018

Cystic Fibrosis – Pipeline by Aridis Pharmaceuticals Inc, H2 2018

Cystic Fibrosis – Pipeline by Arrowhead Pharmaceuticals Inc, H2 2018

Cystic Fibrosis – Pipeline by AstraZeneca Plc, H2 2018

Cystic Fibrosis – Pipeline by Boehringer Ingelheim GmbH, H2 2018

Cystic Fibrosis – Pipeline by Calithera Biosciences Inc, H2 2018

Cystic Fibrosis – Pipeline by Catabasis Pharmaceuticals Inc, H2 2018

Cystic Fibrosis – Pipeline by Celtaxsys Inc, H2 2018

Cystic Fibrosis – Pipeline by Chiesi Farmaceutici SpA, H2 2018

Cystic Fibrosis – Pipeline by Cilian AG, H2 2018

Cystic Fibrosis – Pipeline by CRISPR Therapeutics, H2 2018

Cystic Fibrosis – Pipeline by Cyclacel Pharmaceuticals Inc, H2 2018

Cystic Fibrosis – Pipeline by Cyclenium Pharma Inc, H2 2018

Cystic Fibrosis – Pipeline by DiscoveryBiomed Inc, H2 2018

Cystic Fibrosis – Pipeline by Editas Medicine Inc, H2 2018

Cystic Fibrosis – Pipeline by Eloxx Pharmaceuticals Inc, H2 2018

Cystic Fibrosis – Pipeline by Enterprise Therapeutics Ltd, H2 2018

Cystic Fibrosis – Pipeline by Errant Gene Therapeutics LLC, H2 2018

Cystic Fibrosis – Pipeline by ethris GmbH, H2 2018

Cystic Fibrosis – Pipeline by Evaxion Biotech ApS, H2 2018

Cystic Fibrosis – Pipeline by Galapagos NV, H2 2018

Cystic Fibrosis – Pipeline by Generation Bio Corp, H2 2018

Cystic Fibrosis – Pipeline by Grifols SA, H2 2018

Cystic Fibrosis – Pipeline by Grupo Praxis Pharmaceutical SA, H2 2018

Cystic Fibrosis – Pipeline by Helperby Therapeutics Group Ltd, H2 2018

Cystic Fibrosis – Pipeline by Homology Medicines, Inc., H2 2018

Cystic Fibrosis – Pipeline by Horizon Pharma Plc, H2 2018

Cystic Fibrosis – Pipeline by ID Pharma Co Ltd, H2 2018

Cystic Fibrosis – Pipeline by Idorsia Pharmaceutical Ltd, H2 2018

Cystic Fibrosis – Pipeline by Immun System IMS AB, H2 2018

Cystic Fibrosis – Pipeline by Insmed Inc, H2 2018

Cystic Fibrosis – Pipeline by Invion Ltd, H2 2018

Cystic Fibrosis – Pipeline by Ionis Pharmaceuticals Inc, H2 2018

Cystic Fibrosis – Pipeline by JHL Biotech Inc, H2 2018

Cystic Fibrosis – Pipeline by Johnson & Johnson, H2 2018

Cystic Fibrosis – Pipeline by Kamada Ltd, H2 2018

Cystic Fibrosis – Pipeline by Kyorin Pharmaceutical Co Ltd, H2 2018

Cystic Fibrosis – Pipeline by Lamellar Biomedical Ltd, H2 2018

Cystic Fibrosis – Pipeline by Laurent Pharmaceuticals Inc, H2 2018

Cystic Fibrosis – Pipeline by Lexicon Pharmaceuticals Inc, H2 2018

Cystic Fibrosis – Pipeline by Microbion Corp, H2 2018

Cystic Fibrosis – Pipeline by Novabiotics Ltd, H2 2018

List of Figures

List of Figures

Number of Products under Development for Cystic Fibrosis, H2 2018

Number of Products under Development by Companies, H2 2018

Number of Products ...

List of Figures

Number of Products under Development for Cystic Fibrosis, H2 2018

Number of Products under Development by Companies, H2 2018

Number of Products under Development by Universities/Institutes, H2 2018

Number of Products by Top 10 Targets, H2 2018

Number of Products by Stage and Top 10 Targets, H2 2018

Number of Products by Top 10 Mechanism of Actions, H2 2018

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2018

Number of Products by Routes of Administration, H2 2018

Number of Products by Stage and Routes of Administration, H2 2018

Number of Products by Top 10 Molecule Types, H2 2018

Number of Products by Stage and Top 10 Molecule Types, H2 2018

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports